查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048048

鼻竇炎治療市場－全球產業規模、佔有率、趨勢、機會、預測：按疾病類型、給藥途徑、地區和競爭格局分類，2021-2031年

Sinusitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Route of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球鼻竇炎治療市場預計將從 2025 年的 36 億美元成長到 2031 年的 45.9 億美元，複合年成長率為 4.13%。

該市場涵蓋多種藥物療法，包括皮質類固醇和抗生素，以及旨在緩解鼻竇發炎的外科手術，例如球囊鼻竇成形術。推動該領域成長的關鍵因素包括慢性呼吸系統疾病盛行率上升、環境污染加劇以及老年人口不斷成長（老年人更容易出現鼻竇問題）。這些潛在因素維持了對非處方治療方案和先進醫療程序的雙重需求。

市場概覽
預測期 2027-2031
市場規模：2025年 36億美元
市場規模：2031年 45.9億美元
複合年成長率：2026-2031年 4.13%
成長最快的細分市場 慢性鼻竇炎
最大的市場 北美洲

限制市場潛力的主要挑戰之一是，由於全球對抗菌素抗藥性的擔憂，抗生素處方監管日益嚴格，這導致藥物銷售即時，並促使人們轉向保守治療。儘管存在這些監管障礙，但疾病帶來的沉重負擔仍然是維持市場重要性的重要因素。根據美國耳鼻喉頭頸外科學會預測，到2025年，約有12%的美國成年人將患有鼻竇炎。如此高的盛行率確保了對治療方法研發的持續投入，即便在推廣合理使用抗生素的努力不斷推進的同時，也需要加大投入。

市場促進因素

微創手術技術的廣泛應用是市場成長的主要動力，從根本上改變了慢性鼻竇炎的治療模式。鼻竇擴張系統和類固醇釋放植入的技術進步使臨床醫生能夠在門診進行手術，與功能性內視鏡鼻竇手術相比，大大縮短了患者的恢復時間。這種向門診手術的轉變促使醫療設備製造商擴展其耳鼻喉科（ENT）產品系列，因為它可以降低醫療成本並提高患者處理能力。根據Medtronic於2024年8月發布的“第一季業績”，包括耳鼻喉科業務在內的神經科學部門銷售額達到23.2億美元，表明市場對先進手術技術的持續需求。

同時，生物製藥和標靶療法的進步正在創造顯著價值，尤其對於對皮質類固醇無反應的難治性慢性鼻竇炎伴隨鼻息肉患者而言更是如此。針對特定發炎路徑的單株抗體提供了一種無需反覆手術即可縮小息肉體積並恢復鼻竇氣流的機制。這些治療方法的商業性成功凸顯了在重症病例中迫切需要有效的治療策略。根據再生元製藥公司於2024年10月發布的2024年第三季財報，Dupixent的全球銷售額成長了23%，達到38.2億美元，凸顯了生物製藥的快速普及。此外，正如賽諾菲在2024年9月關於FDA核准用於青少年的新聞稿中所述，美國約有9000名青少年患有未控制的慢性鼻竇炎，尤其是伴有鼻息肉，他們是市場滲透的關鍵目標群體。

市場挑戰

全球鼻竇炎治療市場對抗生素處方的嚴格監管是擴大銷售量的主要障礙。隨著世界各地衛生部門加強對抗抗菌素抗藥性，嚴格的抗菌藥物使用方案的實施迫使醫療服務提供者優先考慮保守治療策略，而非即時進行藥物治療。這種監管壓力實際上限制了一線抗生素治療的市場，因為醫生越來越需要在開處方前檢驗病原菌。因此，濫用抗生素治療急性鼻竇炎症狀的情況正在減少，這直接影響了依賴高處方量來維持收入穩定的製藥公司的銷售。

監管機構試圖消除不合理處方行為的現狀，而近期的數據凸顯了這項法規影響之大。根據美國疾病管制與預防中心（CDC）統計，到2024年，約有30%的急性鼻竇炎患者被處方了與臨床實務指引建議不符的抗生素。隨著法規結構的加強以糾正這種不一致性，市場將面臨商業性機會的直接萎縮。這種強制性的處方行為糾正措施對市場擴張構成了切實的限制，因為在現代治療標準下，相當一部分傳統需求將被重新歸類為不必要的。

市場趨勢

呼氣給藥系統 (EDS) 的興起正在改變慢性鼻竇炎的非手術治療方式，它克服了傳統鼻用皮質類固醇噴霧劑的局限性——這些噴霧劑往往無法到達上鼻竇和後鼻竇。這一趨勢的動力在於新型裝置的商業化，這些裝置利用自然呼氣機制將藥物深入輸送到發炎組織。這為那些已用盡現有治療方案或希望延後手術的患者提供了新的治療選擇。 EDS-Fluticasone核准用於治療無鼻息肉的慢性鼻竇炎，這有力地支持了該方法的有效性，顯著擴大了目標患者群體，使其不再局限於傳統的「僅限鼻息肉」適應症。根據 Optinose 公司於 2025 年 3 月發布的“2024 年第四季度及全年財務業績”，Xhance 第四季度的淨銷售額成長了 13%，達到 2240 萬美元，這反映出這種靶向給藥機制正日益被廣泛接受，成為標準治療方案。

同時，人工智慧（AI）在耳鼻喉科診斷和術前規劃的應用，正在提升複雜鼻竇手術的精準度。市場參與者正將機器學習演算法整合到導航系統和內視鏡平台中，以產生即時3D解剖圖，使外科醫生能夠比傳統成像技術更精確地觀察關鍵結構。這些技術的整合正在加速醫院耳鼻喉科老舊醫療設備的現代化，最大限度地降低術中風險，並最佳化手術流程。對這類先進智慧生態系統解決方案的需求，已清楚地體現在業界領導企業的財務表現中。根據史賽克公司於2025年10月發布的2025年第三季財報，包括這些先進導航技術在內的「醫療、外科及神經技術」業務板塊淨銷售額達到38億美元，年增14.4%，這主要得益於醫療設備的強勁需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球鼻竇炎治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疾病類型（慢性鼻竇炎、急性鼻竇炎、亞急性鼻竇炎）
    • 給藥途徑（鼻內、口服、注射、局部用藥）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美鼻竇炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲鼻竇炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區鼻竇炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲鼻竇炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲鼻竇炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球鼻竇炎治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc
  • Bayer AG
  • GSK plc
  • Fresenius Kabi AG
  • OptiNose US, Inc
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Inc.
  • Stryker Corporation.
  • Medtronic plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20238

The Global Sinusitis Treatment Market is projected to expand from USD 3.60 Billion in 2025 to USD 4.59 Billion by 2031, reflecting a CAGR of 4.13%. This market encompasses a variety of pharmacological treatments, including corticosteroids and antibiotics, alongside surgical options such as balloon sinuplasty designed to relieve inflammation in the paranasal sinuses. Key drivers of growth in this sector include the increasing incidence of chronic respiratory conditions, rising levels of environmental pollution, and a growing geriatric population that is increasingly prone to sinonasal issues. These underlying factors consistently sustain demand for both over-the-counter management solutions and advanced medical procedures.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.60 Billion
Market Size 2031USD 4.59 Billion
CAGR 2026-20314.13%
Fastest Growing SegmentChronic Sinusitis
Largest MarketNorth America

A significant challenge limiting market potential is the increasing regulatory strictness regarding antibiotic prescriptions due to global resistance concerns, which slows immediate pharmaceutical sales and necessitates a shift toward conservative management. Despite these regulatory barriers, the substantial burden of the disease remains a powerful force maintaining market relevance. According to the American Academy of Otolaryngology-Head and Neck Surgery, sinusitis is expected to affect approximately 12% of adults in the United States in 2025. This high prevalence ensures continued investment in therapeutic development, even as the push for antibiotic stewardship continues.

Market Driver

The rising adoption of minimally invasive surgical techniques serves as a primary catalyst for market growth, fundamentally changing the treatment landscape for chronic rhinosinusitis. Technological advancements in sinus dilation systems and steroid-releasing implants enable clinicians to perform interventions in outpatient settings, offering reduced recovery times compared to traditional functional endoscopic sinus surgery. This transition toward office-based procedures lowers healthcare costs and improves patient throughput, motivating medical device manufacturers to upgrade their ENT portfolios. According to Medtronic's 'Q1 Fiscal Year 2025 Financial Results' from August 2024, the Neuroscience portfolio, which includes the ENT business, reported revenue of USD 2.32 billion, reflecting sustained demand for advanced procedural technologies.

Simultaneously, progress in biologics and targeted pharmacotherapies is driving significant value, particularly for patients with stubborn chronic rhinosinusitis with nasal polyps who do not respond to corticosteroids. Monoclonal antibodies that target specific inflammatory pathways offer a mechanism to reduce polyp size and restore sinus patency without the need for repeated surgical intervention. The commercial success of these therapies highlights the urgent clinical need for effective management strategies in severe cases. According to Regeneron Pharmaceuticals' 'Third Quarter 2024 Financial Results' in October 2024, Dupixent global net sales increased by 23% to USD 3.82 billion, underscoring the rapid uptake of biologic treatments. Furthermore, as noted by Sanofi in a September 2024 press release regarding FDA approval for adolescents, there are approximately 9,000 adolescents in the U.S. specifically struggling with uncontrolled chronic rhinosinusitis with nasal polyps, representing a critical demographic for market penetration.

Market Challenge

Regulatory stringency regarding antibiotic prescriptions poses a substantial obstacle to volume growth in the global sinusitis treatment market. As global health authorities ramp up efforts to combat antimicrobial resistance, the implementation of rigid stewardship programs is compelling healthcare providers to prioritize conservative management strategies over immediate pharmacological intervention. This regulatory pressure effectively limits the addressable market for first-line antibiotic therapies, as physicians are increasingly required to validate bacterial etiology before prescribing. Consequently, the automatic use of antibiotics for acute sinus symptoms is declining, directly reducing the unit sales of pharmaceutical manufacturers who rely on high-volume prescription rates for revenue stability.

The magnitude of this restrictive impact is highlighted by recent data regarding the prevalence of non-compliant prescribing that regulators aim to eliminate. According to the Centers for Disease Control and Prevention, in 2024, approximately 30% of patient encounters for acute sinusitis resulted in antibiotic prescriptions that were inconsistent with clinical practice guideline recommendations. As regulatory frameworks tighten to correct this discrepancy, the market faces a direct contraction in commercial opportunity. This enforced correction in prescribing behavior creates a tangible limit on market expansion, as a significant portion of historical demand is reclassified as unnecessary under modern therapeutic standards.

Market Trends

The rise of Exhalation Delivery Systems (EDS) is reshaping the non-surgical management of chronic rhinosinusitis by addressing the limitations of standard intranasal corticosteroid sprays, which often fail to reach the superior and posterior sinus cavities. This trend is driven by the commercialization of novel devices that utilize natural exhalation mechanisms to propel medication deep into inflamed tissues, offering a therapeutic alternative for patients who have exhausted over-the-counter options but wish to delay surgery. This approach gained significant validation with the regulatory approval of EDS-fluticasone for chronic rhinosinusitis without nasal polyps, significantly widening the addressable patient pool beyond the traditional polyp-only indication. According to Optinose's 'Fourth Quarter and Full Year 2024 Financial Results' from March 2025, Xhance net revenue for the fourth quarter increased by 13% to USD 22.4 million, reflecting the growing adoption of this targeted delivery mechanism as a standard of care.

Concurrently, the integration of artificial intelligence into ENT diagnostics and preoperative planning is enhancing the precision of complex sinus interventions. Market players are embedding machine learning algorithms into navigation systems and endoscopic platforms to generate real-time 3D anatomical maps, allowing surgeons to visualize critical structures with greater accuracy than conventional imaging. This technological convergence minimizes intraoperative risks and optimizes surgical workflows, driving the replacement of legacy capital equipment in hospital otolaryngology departments. The demand for such advanced intelligent ecosystem solutions is evident in the financial performance of key sector leaders. According to Stryker's 'Third Quarter 2025 Financial Results' from October 2025, net sales for the Medical and Surgical and Neurotechnology segment, which houses these advanced navigation technologies, reached USD 3.8 billion, representing a 14.4% increase driven by robust demand for capital equipment.

Key Market Players

  • Abbott Laboratories Inc
  • Bayer AG
  • GSK plc
  • Fresenius Kabi AG
  • OptiNose US, Inc
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Inc.
  • Stryker Corporation.
  • Medtronic plc

Report Scope

In this report, the Global Sinusitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sinusitis Treatment Market, By Disease Type

  • Chronic Sinusitis
  • Acute Sinusitis
  • Sub-Acute Sinusitis

Sinusitis Treatment Market, By Route of Administration

  • Nasal
  • Oral
  • Injectable
  • Topical

Sinusitis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sinusitis Treatment Market.

Available Customizations:

Global Sinusitis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Sinusitis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Chronic Sinusitis, Acute Sinusitis, Sub-Acute Sinusitis)
    • 5.2.2. By Route of Administration (Nasal, Oral, Injectable, Topical)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Sinusitis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Sinusitis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Route of Administration
    • 6.3.2. Canada Sinusitis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Route of Administration
    • 6.3.3. Mexico Sinusitis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Route of Administration

7. Europe Sinusitis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Sinusitis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Route of Administration
    • 7.3.2. France Sinusitis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Route of Administration
    • 7.3.3. United Kingdom Sinusitis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Route of Administration
    • 7.3.4. Italy Sinusitis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Route of Administration
    • 7.3.5. Spain Sinusitis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Route of Administration

8. Asia Pacific Sinusitis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Sinusitis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Route of Administration
    • 8.3.2. India Sinusitis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Route of Administration
    • 8.3.3. Japan Sinusitis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Route of Administration
    • 8.3.4. South Korea Sinusitis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Route of Administration
    • 8.3.5. Australia Sinusitis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Route of Administration

9. Middle East & Africa Sinusitis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Sinusitis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Route of Administration
    • 9.3.2. UAE Sinusitis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Route of Administration
    • 9.3.3. South Africa Sinusitis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Route of Administration

10. South America Sinusitis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Sinusitis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Route of Administration
    • 10.3.2. Colombia Sinusitis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Route of Administration
    • 10.3.3. Argentina Sinusitis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Sinusitis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bayer AG
  • 15.3. GSK plc
  • 15.4. Fresenius Kabi AG
  • 15.5. OptiNose US, Inc
  • 15.6. Dr. Reddy's Laboratories Ltd.
  • 15.7. Cipla Inc.
  • 15.8. Stryker Corporation.
  • 15.9. Medtronic plc

16. Strategic Recommendations

17. About Us & Disclaimer